文献速递膀胱癌与上尿路尿路上皮癌

吉西他滨-顺铂化疗诱导膀胱癌Nectin-4下调及恩诺单抗维多汀耐药

Gemcitabine-Cisplatin Chemotherapy Induces Nectin-4 Downregulation and Enfortumab Vedotin Resistance in Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2026-09-08

该研究利用患者来源的膀胱癌模型,发现吉西他滨-顺铂(GC)化疗获得性耐药细胞中恩诺单抗维多汀(EV)靶点Nectin-4膜表达下调,并出现EV交叉耐药。两独立人类膀胱癌队列验证了新辅助及辅助GC化疗期间Nectin-4表达降低。转录组提示GC耐药与Nectin-4下调关联上皮-间质转化(EMT)样表型,TGF-beta通路可能为潜在脆弱点。

要点

  • GC化疗耐药膀胱癌细胞出现Nectin-4膜表达下调及EV交叉耐药。
  • 新辅助和辅助GC化疗期间肿瘤Nectin-4表达降低在人类队列中被验证。
  • GC耐药与Nectin-4下调关联EMT样转录重编程,TGF-beta通路为潜在靶点。

核心结论

  • 铂类化疗可能通过诱导EMT样转录重编程导致膀胱癌Nectin-4丢失和EV耐药。
  • 铂类治疗后评估膜性Nectin-4表达对EV治疗选择可能尤其重要。

研究设计与样本

  • 利用新型患者来源膀胱癌模型进行体外GC耐药选择。
  • 在两个独立人类膀胱癌队列中验证Nectin-4表达变化。

主要发现

  • GC耐药(GC/R)细胞中EV靶点Nectin-4下调并出现EV交叉耐药。
  • 新辅助治疗期间配对经尿道切除与根治性膀胱切除/淋巴结标本中膜性Nectin-4表达降低。
  • 辅助GC化疗期间原发肿瘤与远处转移灶中Nectin-4表达降低。
  • 转录组分析显示GC耐药和Nectin-4下调与EMT样表型相关。
  • 大规模药物筛选和转录组数据提示GC/R细胞潜在脆弱性与TGF-beta信号通路相关。

临床怎么用

  • 在铂类治疗后考虑EV治疗时,可评估膜性Nectin-4表达。
  • 可探索化疗诱导的TGF-beta通路等替代可成药脆弱点以优化治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibody-drug conjugates (ADCs), particularly enfortumab vedotin (EV) in combination with pembrolizumab, have emerged as transformative treatments for advanced bladder cancer (BC). However, platinum-based chemotherapy, especially gemcitabine-cisplatin (GC), remains a widely used, first-line standard globally. This study investigated the impact of GC-therapy on subsequent ADC responsiveness. Using novel, patient-derived BC models, in vitro selection for acquired GC-resistance consistently resulted in downregulation of the EV target, Nectin-4, and corresponding EV cross-resistance in GC-resistant (GC/R) cells. This decrease in membranous Nectin-4 expression was validated in two independent human BC cohorts: (1) matched transurethral resections and radical cystectomy/lymph node specimens during neoadjuvant therapy and (2) primary tumors and distant metastases during adjuvant GC chemotherapy. Transcriptomic profiling indicated that GC-resistance and Nectin-4 downregulation were linked to a transcriptional shift toward an epithelial-to-mesenchymal transition (EMT)-like phenotype. Large-scale drug screening and transcriptomic data highlighted potential vulnerabilities in GC/R cells, notably associated with the transforming growth factor beta (TGF-beta) signaling pathway. These findings suggest that platinum-based chemotherapy may promote EMT-like transcriptional reprogramming in BC, associated with Nectin-4 loss and EV resistance. As such, assessing membranous Nectin-4 expression prior to EV therapy might be particularly relevant in postplatinum settings. Additionally, identifying alternative, chemotherapy-induced druggable vulnerabilities can inform more effective treatment strategies.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Nössing C, Prantl I, Grausenburger R, et al. Gemcitabine-Cisplatin Chemotherapy Induces Nectin-4 Downregulation and Enfortumab Vedotin Resistance in Bladder Cancer. Eur Urol Oncol. 2026. PMID: 42711240. doi:10.1016/j.euo.2026.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。